Clinical Trial Update: Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 antibody in combination with bevacizumab for high-risk gestational trophoblastic neoplasia after combined chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gestational Trophoblastic Neoplasia

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Women's Hospital School Of Medicine Zhejiang University | Conditions: Gestational Trophoblastic Neoplasia | Phase 2 | Status: UNKNOWN